The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
BUSINESS
Takeda-PRA Joint Venture in Japan to Be Formed on June 1
Takeda Pharmaceutical said on April 7 that its wholly owned subsidiary set up last month to take over some functions from the Japanese giant’s drug development division will become a joint venture with US CRO PRA Health Sciences, as previously…
To read the full story
Related Article
- Dissolving JV with Takeda, PRA Launches Independent CRO Biz in Japan
July 24, 2019
- Takeda, PRA to Launch JV in Japan to Take Over 140 Employees
February 16, 2017
BUSINESS
- Daito Secures China Approval for EquMet Generic
January 13, 2026
- Japan Ethical Drug Sales Edge Up 0.4% in November: Crecon
January 13, 2026
- Bayer/Santen to Launch Eylea Bio-AG on February 2
January 9, 2026
- Nxera Bags Japan, Select APAC Rights to Santhera’s DMD Therapy
January 9, 2026
- Keio Offshoot Taps Alfresa Know-How for Cell Therapy Push, Bets on Dual iPS Strategy
January 9, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…